24Jan 2023
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor. To report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin disease. Ruxolitinib cream demonstrated rapid improvement in itch in patients with mild to moderate AD that was sustained for 8 weeks. Significantly more patients applying ruxolitinib cream achieved itch NRS2 within approximately 12 h and itch NRS4 by Day 2 versus vehicle.

  • #dermatology

Like

Save

Share